| Overview |
| bs-1856R-Cy7 |
| MMP-16 Polyclonal Antibody, Cy7 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse |
| Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MMP-16 |
| 501-607/607 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4325 |
| P51512 |
| Cell membrane, Extracellular matrix |
| MMP-X2; C8orf57; MT-MMP2; MT-MMP3; MT3-MMP; Matrix metalloproteinase-16; MMP-16; Membrane-type matrix metalloproteinase 3; MT-MMP 3; MTMMP3; Membrane-type-3 matrix metalloproteinase; MT3MMP; MMP16; MMPX2 |
| Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz